You are here

ICER

Drug price hikes without new evidence upped spending by $1.2B, ICER says

Drug price hikes without new evidence upped spending by $1.2B, ICER says

MedCity News

Flag link:

Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says

Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says

BioPharma Dive

Gilead Sciences

Flag link:

Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds

Vertex's cystic fibrosis drugs work, but they're too expensive, ICER finds

Endpoints

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

What can Linux and Mozilla teach ICER about how to do drug value assessments?

What can Linux and Mozilla teach ICER about how to do drug value assessments?

Pharmaforum

drug value assessments

Flag link:

New sickle cell drugs priced too high, ICER says

New sickle cell drugs priced too high, ICER says

BioPharma Dive

sickle cell disease

Global Blood Therapeutics

Flag link:

In final report, ICER appears to have a change of heart on new acute migraine therapies

In final report, ICER appears to have a change of heart on new acute migraine therapies

Endpoints

Flag link:

Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER

Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER

Endpoints

sickle cell disease

Global Blood Therapeutics

Emmaus Life Sciences

Flag link:

ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus

ICER Warns of ‘Short-Term Budget Challenges’ with Novo’s Rybelsus

Xtalks

oral semaglutide

Flag link:

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

ICER says ‘marginal’ benefits for AbbVie’s new RA drug

Pharmaforum

rheumatoid arthritis

Flag link:

ICER draws new gene therapy pricing framework

ICER draws new gene therapy pricing framework

Biopharma Dive

Flag link:

U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions

U.S. Sponsors Of Health Insurance Lack Evidence-Based Transparency In Formulary Decisions

Forbes

Flag link:

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

J&J's Xarelto, Amarin's Vascepa are cost-effective, not budget friendly — ICER

Endpoints

Flag link:

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

ICER says AbbVie’s Rinvoq for RA may be cost-effective but still questions the value of JAK class

Fierce Pharma

rheumatoid arthritis

Flag link:

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Humira, Rituxan top list of U.S. drugs with biggest price increases -report

Yahoo/Reuters

Flag link:

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

ICER pulls report blasting ‘marginal’ RA drugs, citing need to rethink its approach

Fierce Pharma

rheumatoid arthritis

Flag link:

ICER dings Novo's new oral diabetes drug

ICER dings Novo's new oral diabetes drug

Biopharma Dive

oral semaglutide

Boehringer Ingelheim

Flag link:

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

New peanut allergy therapies aren’t as effective — or nearly as inexpensive — as abstinence, says ICER

Endpoints

Aimmune Therapeutics

DBV Technologies

Flag link:

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Cost-effectiveness watchdogs skewer Novartis' MS drug Mayzent and J&J's depression spray Spravato

Fierce Pharma

Flag link:

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

UPDATED: Sarepta's Exondys 51 is not cost-effective, nor particularly beneficial for DMD patients — ICER

Endpoints

Duchenne Muscular Dystrophy

Sarepta Therapeutics

Flag link:

ICER seeks to make drug price research more accessible

ICER seeks to make drug price research more accessible

Biopharma Dive

Flag link:

Pages